Abstract:Heparin and its low-molecular-weight heparin derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications, including kidney dialysis, cardiopulmonary bypass, and in the management of venous thromboembolism. Currently, these drugs are derived from livestock, primarily porcine intestine and less frequently bovine intestine and bovine lung. The worldwide dependence on the pig as a single dominant animal species has made the supply chain for this critical drug quite fragile, leading to the search for other sources of these drugs, including the expanded use of bovine tissues. A number of laboratories are now also examining the similarities between heparin and low-molecular-weight heparins prepared from porcine and ovine tissues. This study was designed to compare low-molecular-weight heparin prepared from ovine heparin through chemical beta-elimination, a process currently used to prepare the low-molecular-weight heparin, enoxaparin. Using top-down, bottom-up, and compositional analyses as well as bioassays, low-molecular-weight heparin derived from ovine intestine was shown to closely resemble enoxaparin. Moreover, the compositions of daughter low-molecular-weight heparins prepared from three unfractionated ovine parent heparins were compared. Ovine enoxaparins had similar molecular weight and in vitro anticoagulant activities as Lovenox. Some disaccharide compositional, oligosaccharide composition at the reducing and nonreducing ends and intact chain compositional differences could be observed between porcine enoxaparin and ovine low-molecular-weight heparin. The similarity of these ovine and porcine heparin products suggests that their preclinical evaluation and ultimately clinical assessment is warranted.

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.

Structure-based engineering of heparinase I with improved specific activity for degrading heparin

A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions

Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies

Development of Low Molecular Weight Heparin by H2O2/ascorbic Acid with Ultrasonic Power and Its Anti-Metastasis Property.

Analysis of heparinase derived LMWH products using a MHC 2D LC system linked to Q-TOF MS

Production of Heparin Oligosaccharides by Fusion Protein of MBP–heparinase I and the Enzyme Thermostability

Research Progress of Low Molecular Weight Heparin

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Characteristics of low molecular weight heparin production by an ultrafiltration membrane bioreactor using maltose binding protein fused heparinase I

Enzymatic access to the rare ΔUA (1→4) Glc 3, 6, N-sulfated heparin disaccharide, implications for heparin quality control

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Analysis of sulfates on low molecular weight heparin using mass spectrometry: structural characterization of enoxaparin

Nanopore-regulated in situ polymerization for synthesis of homogeneous heparan sulfate with low dispersity

Comparison Of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin